Pre-Existing Intrarenal Parvovirus B19 Infection May Relate to Antibody-Mediated Rejection in Pediatric Kidney Transplant Patients
暂无分享,去创建一个
L. Barzon | G. Gallinella | A. Carraro | E. Manaresi | Nicola Bertazza Partigiani | S. Negrisolo | E. Benetti | Diana Marzenta
[1] P. Kalra,et al. Kidney Transplant-Associated Viral Infection Rates and Outcomes in a Single-Centre Cohort , 2022, Viruses.
[2] T. Ngamprasertchai,et al. Efficacy and Safety of Antiviral Agents in Preventing Allograft Rejection Following CMV Prophylaxis in High-Risk Kidney Transplantation: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials , 2022, Frontiers in Cellular and Infection Microbiology.
[3] Jianghua Chen,et al. Donor-Derived Human Parvovirus B19 Infection in Kidney Transplantation , 2021, Frontiers in Cellular and Infection Microbiology.
[4] E. Kamil,et al. Use of Rituximab for persistent EBV DNAemia, and Its effect on donor‐specific antibody development in pediatric renal transplant recipients: A case series , 2021, Pediatric transplantation.
[5] L. Riella,et al. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review. , 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] Chih-Yu Yang,et al. BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection , 2021, Viruses.
[7] A. Naik,et al. Increasing net immunosuppression after BK polyoma virus infection , 2020, Transplant infectious disease : an official journal of the Transplantation Society.
[8] C. Thongprayoon,et al. Epidemiology of parvovirus B19 and anemia among kidney transplant recipients: A meta-analysis , 2020, Urology annals.
[9] M. López-Hoyos,et al. Acute Rejection Following Kidney Transplantation: State of Art and Future Perspectives. , 2020, Current pharmaceutical design.
[10] N. Sharma,et al. Parvovirus Infection-Related Anemia after Kidney Transplantation , 2020, Case reports in transplantation.
[11] M. Ardura,et al. Human parvovirus B19 in solid organ transplantation: Guidelines from the American society of transplantation infectious diseases community of practice , 2019, Clinical transplantation.
[12] P. Nickel,et al. Prophylaxis and treatment of Pneumocystis Jirovecii pneumonia after solid organ transplantation. , 2018, Pharmacological research.
[13] M. Choe,et al. Long-term prognosis of BK virus-associated nephropathy in kidney transplant recipients , 2018, Kidney research and clinical practice.
[14] M. Stegall,et al. De novo donor‐specific antibody following BK nephropathy: The incidence and association with antibody‐mediated rejection , 2018, Clinical transplantation.
[15] Silvi Shah,et al. Severe BK polyomavirus‐induced hemorrhagic cystitis in a kidney transplant recipient with the absence of renal allograft involvement , 2018, Transplant infectious disease : an official journal of the Transplantation Society.
[16] G. Schwartz,et al. Measurement and Estimation of Glomerular Filtration Rate in Children. , 2017, Advances in chronic kidney disease.
[17] R. Khanna,et al. BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies , 2017, Clinical Microbiology Reviews.
[18] T. Muthukumar,et al. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[19] N. Goto,et al. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury , 2016, Transplantation.
[20] J. Pober,et al. Blocking MHC class II on human endothelium mitigates acute rejection. , 2016, JCI insight.
[21] C. Haisch,et al. Onset and progression of de novo donor‐specific anti‐human leukocyte antigen antibodies after BK polyomavirus and preemptive immunosuppression reduction , 2015, Transplant infectious disease : an official journal of the Transplantation Society.
[22] V. Dharnidharka,et al. Viral surveillance and subclinical viral infection in pediatric kidney transplantation , 2015, Pediatric Nephrology.
[23] R. Bloom,et al. Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies. , 2015, Journal of the American Society of Nephrology : JASN.
[24] H. Fechner,et al. Antibody-Mediated Enhancement of Parvovirus B19 Uptake into Endothelial Cells Mediated by a Receptor for Complement Factor C1q , 2014, Journal of Virology.
[25] Sandeep Kumar Dhanda,et al. Designing of interferon-gamma inducing MHC class-II binders , 2013, Biology Direct.
[26] L. Mouthon,et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] V. Stefanović,et al. Viral Infection in Renal Transplant Recipients , 2012, TheScientificWorldJournal.
[28] A. Vo,et al. Clinical Aspects of Intravenous Immunoglobulin Use in Solid Organ Transplant Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[29] SUPPORTING TABLES,et al. KDIGO clinical practice guideline for the care of kidney transplant recipients. , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[30] G. Palù,et al. Detection of viral DNA in kidney graft preservation and washing solutions is predictive of posttransplant infections in pediatric recipients. , 2009, The Journal of infectious diseases.
[31] V. Dharnidharka,et al. Post-transplant lymphoproliferative disease , 2009, Pediatric Nephrology.
[32] T. Giese,et al. Endothelial Progenitor Cells Possess Monocyte-like Antigen-presenting and T-cell-Co-stimulatory Capacity , 2009, Transplantation.
[33] G. Palù,et al. Investigation of intrarenal viral infections in kidney transplant recipients unveils an association between parvovirus B19 and chronic allograft injury. , 2009, The Journal of infectious diseases.
[34] Fang Zhou,et al. Molecular Mechanisms of IFN-γ to Up-Regulate MHC Class I Antigen Processing and Presentation , 2009, International reviews of immunology.
[35] B. Tzang,et al. Up-regulation of adhesion molecule expression and induction of TNF-alpha on vascular endothelial cells by antibody against human parvovirus B19 VP1 unique region protein. , 2008, Clinica chimica acta; international journal of clinical chemistry.
[36] E. Blumberg,et al. Viral infection after renal transplantation: surveillance and management. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[37] J. Kopp,et al. Parvovirus B19 and the kidney. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[38] Robin Patel,et al. Parvovirus B19 infection after transplantation: a review of 98 cases. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] B. Einollahi,et al. Signs and symptoms of cytomegalovirus disease in kidney transplant recipients. , 2005, Transplantation proceedings.
[40] A. Edefonti,et al. One‐year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient , 2005, Transplant international : official journal of the European Society for Organ Transplantation.
[41] F. Aiello,et al. Acute rejection and graft survival in renal transplanted patients with viral diseases , 2004, Modern Pathology.
[42] H. Volk,et al. Association between Epstein-Barr virus infection and late acute transplant rejection in long-term transplant patients. , 2001, Transplantation.
[43] F. Zacchello,et al. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. , 2000, Journal of the American Society of Nephrology : JASN.
[44] E. Woodle,et al. Coadministration of Tacrolimus and Mycophenolate Mofetil in Stable Kidney Transplant Patients: Pharmacokinetics and Tolerability , 2000, Journal of clinical pharmacology.
[45] S. Jensik. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. , 1998, Transplantation proceedings.
[46] D Talbot,et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. , 1997, Transplantation.
[47] R. Schoentag,et al. Human parvovirus B19 in bone marrows from adults with acquired immunodeficiency syndrome: a comparative study using in situ hybridization and immunohistochemistry. , 1997, Human pathology.
[48] Joshua Miller,et al. A Comparison Of Tacrolimus (fk506) And Cyclosporine For Immunosuppression After Cadaveric Renal Transplantation1 , 1997 .
[49] H. Volk,et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. , 1994, Lancet.
[50] A. Gaber,et al. Incidence and Factors Associated with De Novo DSA After BK Viremia in Renal Transplant Recipients. , 2016, Clinical transplants.